Pfizer Getting out of Cox-2 Litigation

Pfizer announced this week that it has reached agreements to settle all of its Cox-2 litigation — Bextra and Celebrex — for just shy of $900 million.  The settlement will resolve personal injury claims as well as state AG and third party payor claims.

–BC
(who has done consulting for pharma, including in the Cox-2 arena, though not for Pfizer)